Home >  News >  Industry >  Pharma News >  COVID-19: Infections...

COVID-19: Infections reported among Sputnik V trial volunteers

By - Ruchika Sharma
Published On 2020-10-29 09:22 GMT   |   Update On 2020-10-29 09:22 GMT
Advertisement

New Delhi: There have been instances of infection among volunteers of Sputnik V trials, the world's first registered vaccine against Covid-19 virus, according to a top official of the developer of the Russian vaccine, said a media report.

This is the reason why the developer of the vaccine, the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry, is considering the possibility of disclosing the data on who among the volunteers were administered the vaccine, before summing up the results of the study, Russian news agency TASS reported on Wednesday.
Earlier, Deputy Research Director of the Gamaleya National Research Center, and Associate Member of the Russian Academy of Sciences, Denis Logunov, reported that trial participants will find out whether they received the vaccine or the placebo only after the end of tests.
The center's director Alexander Gintsburg reported that the last group of volunteers out of the total of 40,000 may be inoculated by the end of January 2021.
Advertisement
"...Apparently, there are (coronavirus) infections (among the post-registration trials participants). At some point in mid-November the provisional results will be summed up, then we will find out the difference between the placebo and the test samples," Gintsburg was quoted as saying to TASS.
In response to a question on how the results can be obtained before the end of the study if the data can be disclosed only after its completion, the director said that currently the center is thinking of introducing relevant amendments to the legislation.
The center's director also explained that coronavirus infections among the volunteers may be related to the fact that an individual wasn't vaccinated, that is, received the placebo.
On August 11, Russia became the first country in the world to register the vaccine against coronavirus which was named Sputnik V.
Russia faced criticism for approving a vaccine before conducting crucial phase-3 trials.
Post-registration trials of the preparation started in Moscow on September 7, with the first volunteers receiving the vaccine on September 9.
In all, 40,000 people participate in the program, 10,000 of whom will receive a placebo instead of the vaccine, TASS reported.
Earlier, the Janssen-Cilag company, the pharmaceutical division of US multinational Johnson & Johnson, temporarily suspended clinical trials in Brazil of a vaccine against Covid-19.
Before that, the Oxford Covid-19 vaccine trial was temporarily paused as one of the participants reported a suspected severe adverse reaction. The trial resumed after a safety review.

Read also: COVID vaccine: RDIF seeks Sputnik V speedy registration, prequalification from WHO




Tags:    
Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Agitated Over Late Medicine Delivery, Man Fires Air Gun, Booked for Attempt to Murder

Sun Pharma, Alembic Pharma and 1 other recall products in US

Sun Pharma's Dapagliflozin, Glimepiride, Metformin FDC Fails to Secure CDSCO Panel Nod Over Safety, Utility Concerns

Submit BE Raw Data, Interaction Study on Dapagliflozin-Rosuvastatin FDC: Expert Panel Tells Pure and Cure

Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan for previously treated Advanced EGFR Mutated Non Small Cell Lung Cancer

Alembic Pharma wins USFDA approval for pulmonary arterial hypertension drug Macitentan

Merck, Daiichi Sankyo Ifinatamab deruxtecan granted Breakthrough Therapy Designation by USFDA for pretreated extensive-stage small cell lung cancer

Boehringer Ingelheim, Palatin Technologies to develop melanocortin receptor targeted treatment for retinal diseases